Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study

Purpose: Most patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with a complement protein 5 (C5) inhibitor achieve full control of terminal complement activity and intravascular hemolysis. The minority remains anemic and transfusion dependent despite this control. Etiology for ongoing...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of blood medicine 2022-01, Vol.13, p.425-437
Hauptverfasser:	Shammo, Jamile, Gajra, Ajeet, Patel, Yogesh, Tomazos, Ioannis, Kish, Jonathan, Hill, Anita, Sierra, J. Rafael, Araten, David
Format:	Artikel
Sprache:	eng
Schlagworte:	Anemia Blood Bone marrow bone marrow failure Care and treatment Glycosylated hemoglobin Hemoglobin Hemolysis and hemolysins intravascular hemolysis Laboratories Original Research Patients Pharmaceutical industry real-world Variables
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Purpose: Most patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with a complement protein 5 (C5) inhibitor achieve full control of terminal complement activity and intravascular hemolysis. The minority remains anemic and transfusion dependent despite this control. Etiology for ongoing anemia is multifactorial and includes bone marrow failure, breakthrough hemolysis, extravascular hemolysis (EVH) and nutritional deficiencies. Patients and Methods: To evaluate the potential etiologies of hemoglobin levels
ISSN:	1179-2736 1179-2736
DOI:	10.2147/JBM.S361863